Summary
Up to 15% of women with breast cancer have locally advanced disease at diagnosis. The poor response of these patients to local therapy alone and the frequent development of disseminated disease suggest that early intensive systemic therapy may benefit these women. Twenty-four patients with non-metastatic, locally advanced, primarily inflammatory, inoperable breast cancer were treated with a 16-week dose-intense chemotherapy regimen as induction therapy. Treatment consisted of 8 repetitive 2-week cycles consisting of 100 mg/m2 cyclophosphamide orally D1-7, 40 mg/m2 doxorubicin intravenously (IV) D1, 1 mg vincristine IV D1, 100 mg/m2 methotrexate IV D1, 10 mg/m2 leucovorin every 6 hours for six oral doses D2-3, and 600 mg/m2 5-FU IV over 2 hours D2. A continuous infusion of 300 mg/m2 5-FU per day was given IV D8-9 of each 2-week cycle. After induction all patients had at least a partial clinical response and were operable; 9/24 (37%) achieved a clinical complete response. All patients underwent at least a simple mastectomy. Pathologic examination revealed no evidence of gross macroscopic tumor in 11/24 patients (46%) and no evidence of microscopic disease in 4/24 patients (17%). Seven of 24 patients (29%) had no microscopic disease in the breast. At a median follow-up of 45 months, there have been 10 relapses in the 24 patients treated with this induction regimen. The actuarial relapse-free survival at 5 years is 58%. Actuarial overall survival at 5 years is 75%. We conclude that this regimen is safe and well-tolerated and that the results of this therapy are sufficiently promising to warrant further study of this regimen in patients with locally advanced breast cancer.
References
Swain SM: Selection of therapy for Stage III breast cancer. Surg Clin North Am 70: 1061–1080, 1990
Parker LM, Boyages J, Eberlein TJ: Inflammatory carcinoma of the breast. In: Harris JR, Hellman S, Henderson IC, Kinne DW (eds) Breast Diseases. 2nd ed. JB Lippincott, Philadelphia, 1991, pp 775–782.
Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR: Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46: 2578–2581, 1986
Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco Met al.: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82: 1539–1545, 1990
Early breast cancer trialists' collaborative group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339: 1–15, 71–85, 1992
Bonadonna G, Valagussa P: Adjuvant systemic therapy for resectable breast cancer. J Clin Oncol 3: 259–275, 1985
Hortobagyi GN, Buzdar AU: Locally advanced breast cancer: A review including the M.D. Anderson experience. In: Ragaz J, Ariel IM (eds) High-risk Breast Cancer. Springer-Verlag, Berlin, 1991, pp 382–415.
Abeloff MD, Beveridge RA, Donehower RC, Fetting JH, Davidson NE, Gordon GG, Waterfield WC, Damron DJ: Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst 82: 570–574, 1990
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
Arriagada R, Mouriesse H, Spielmann M, Mezlini A, Oudinot P, le Chevalier T, Cuvier C, Fontaine F, Travagli JP, May-Levin F, Sarrazin D: Alternating radiotherapy and chemotherapy in non-metastatic inflammatory breast cancer. Int J Radiation Oncology Biol Phys 19: 1207–1210, 1990
Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, Steinberg SM, Lippman ME: Neoadjuvant chemotherapy in the combined modality approach to locally advanced nonmetastatic breast cancer. Cancer Res 47: 3889–3894, 1987
Perloff M, Lesnick GJ, Korzun A, Chu F, Holland JF, Thirlwell MP, Ellison RR, Carey LL, Leone L, Weinberg V, Rice MA, Wood WC: Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. J Clin Oncol 6: 261–269, 1988
Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 1281–1288, 1984
Beveridge RA, Abeloff MD, Donehower RC, Damron DJ, Fetting JH, Waterfield W: Sixteen week dose intense chemotherapy for breast cancer (Abstract). Proc Amer Soc Clin Oncol 7: 13, 1988
Osborne CK, Sunderland MC, Neidhart JA, Ravdin PM, Abeloff MD: Failure of GM-CSF to permit dose-escalation in an every-other-week dose-intense regimen for advanced breast cancer. Annals of Oncology (in press).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Armstrong, D.K., Fetting, J.H., Davidson, N.E. et al. Sixteen week dose intense chemotherapy for inoperable, locally advanced breast cancer. Breast Cancer Res Tr 28, 277–284 (1993). https://doi.org/10.1007/BF00666589
Issue Date:
DOI: https://doi.org/10.1007/BF00666589